Skip to main content

Advertisement

SpringerLink
Log in

Overview of Routes of IgG Administration

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

The use of exogenous serum to provide protection against infections began more than a century ago. Over time, this concept matured and led to the preparation of concentrated immunoglobulin (IgG) products that were safe and effective when delivered subcutaneously (SC) or intramuscularly (IM) but were not ideal for intravenous (IV) use. Continued improvements led to the development of IgG preparations that are safe for either subcutaneous IgG (SCIG) or intravenous IgG (IVIG) delivery and allow providers and patients significant flexibility to develop an effective but manageable treatment plan. Factors that influence the choice of IgG product and delivery method can maximize the therapeutic benefit and provide the best possible quality of life for patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Behring V. Uber das Zustandekommen der Diphterie–Immunitat und der Tetanus–Immunitat bei Thieren. Dtsch Med Wochenschr. 1890;16:1113–4.

    Article  Google Scholar 

  2. Berger M. A history of immunoglobulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368–78.

    Article  PubMed  Google Scholar 

  3. Janeway CA. The development and clinical uses of immunoglobulins: a review. In: Merler E, editor. Immunoglobulins: biological aspects and clinical uses. Washington DC: National Academy of Sciences; 1970. p. 3–14.

    Google Scholar 

  4. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–8.

    PubMed  CAS  Google Scholar 

  5. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1–10.

    PubMed  CAS  Google Scholar 

  6. Gardulf A, Hammarstrom L, Edvard Smith CI. Home treatment of hypogammaglobulinemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

The author is a paid consultant for Baxter Biosciences. He is a grant recipient for Baxter Biosciences and CSL Behring.

Author information

Authors and Affiliations

  1. University of Washington School of Medicine, 1900 9th Ave., C9S-7, Seattle, WA, 98101-1304, USA

    Troy R. Torgerson

Authors
  1. Troy R. Torgerson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Troy R. Torgerson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torgerson, T.R. Overview of Routes of IgG Administration. J Clin Immunol 33 (Suppl 2), 87–89 (2013). https://doi.org/10.1007/s10875-012-9845-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10875-012-9845-2

Keywords

Search

Navigation